Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension

Inflammation

Volumn 36, Issue 2, 2013, Pages 405-412

  Onat, Ahmet Mesut ^a   Pehlivan, Yavuz ^a   Turkbeyler, Ibrahim Halil ^a   Demir, Tuncer ^a   Kaplan, Davut Sinan ^a   Ceribasi, Ali Osman ^b   Orkmez, Mustafa ^a   Tutar, Ediz ^a   Taysi, Seyithan ^a   Sayarlioglu, Mehmet ^c   Kisacik, Bunyamin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

^c KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

palosuran; pulmonary arterial hypertension (PAH); urotensin II antagonist

Indexed keywords

ENDOTHELIN 1; PALOSURAN; TRANSFORMING GROWTH FACTOR BETA1; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART HEMODYNAMICS; HEART INDEX; HEART RIGHT VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; INHIBITION KINETICS; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RAT;

ANIMALS; ARTERIAL PRESSURE; ARTERIOLES; ENDOTHELIN-1; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; PULMONARY ARTERY; QUINOLINES; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1; UREA; UROTENSINS;

RATTUS;

EID: 84879504179     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9559-x     Document Type: Article

References (36)

1. McLaughlin, V.V.; and M.D. McGoon. 2006. Pulmonary arterial hypertension. Circulation 114: 1417-1431.
2. Kim, N.H.S.; and L.J. Rubin. 2002. Endothelin in health and disease: Endothelin receptor antagonists in the management of pulmonary artery hypertension. Journal of Cardiovascular Pharmacology Therapeutics 7: 9-19.
3. Maguire, J.J.; R.E. Kuc, and A.P. Davenport. 2000. Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. British Journal of Pharmacology 131: 441-446.
4. Ames, R.S.; H.M. Sarau, J.K. Chambers, R.N. Willette, N.V. Aiyar, A.M. Romanic, et al. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
5. Hillier, C.; C. Berry, M.C. Petrie, P.J. O'Dwyer, C. Hamilton, A. Brown, et al. 2001. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103: 1378-1381.
6. Giebing, G.; M. Tölle, J. Jürgensen, J. Eichhorst, J. Furkert, M. Beyermann, et al. 2005. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circulation Research 97: 707-715.
7. Djordjevic, T. 2007. Görlach A. Urotensin-II in the lung: A matter for vascular remodelling and pulmonary hypertension? Thrombosis and Haemostasis 98: 952-962.
8. Maguire, J.J.; and A.P. Davenport. 2002. Is urotensin-II the new endothelin? British Journal of Pharmacology 137: 579-588.
9. Pehlivan, Y.; A.M. Onat, G. Comez, and T. Babacan. 2011. Urotensin-II in systemic sclerosis: A new peptide in pathogenesis. Clinical Rheumatology 30: 837-842.
10. Pehlivan, Y.; B. Gogebakan, S. Oztuzcu, M. Ozgen, G.Y. Cetin, R. Bayraktar, et al. 2012. Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II Gene and systemic sclerosis. The Journal of Rheumatology 39: 106-111.
11. Onat, A.M.; I. Turkbeyler, Y. Pehlivan, T. Demir, D.S. Kaplan, S. Taysi, et al. 2010. Urotensin II antogonism with palosuran: A new treatment in pulmonary arterial hypertension. Annals of the Rheumatic Diseases 69(suppl3): 410.
12. Mei, Y.; H. Jin, W. Tian, H. Wang, H. Wang, Y. Zhao, et al. 2011. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats. Pulmonary Pharmacology & Therapeutics 24: 386-393.
13. Clozel, M.; C. Binkert, M. Birker-Robaczewska, C. Boukhadra, S.S. Ding, W. Fischli, et al. 2004. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2- methyl- quinolin-4-yl)-urea sulfate salt): First demonstration of a pathophysiological role of the urotensin system. The Journal of Pharmacology and Experimental Therapeutics 311: 204-212.
14. Alexandru, B.; and M.A. Bogdan. 2001. Monocrotaline induces pulmonary hypertension in animal models. Pneumologia 50: 85-89.
15. Clozel, M.; P. Hess, C. Qiu, S.S. Ding, and M. Rey. 2006. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. The Journal of Pharmacology and Experimental Therapeutics 316: 1115-1121.
16. Stinger, R.B.; V.J. Iacopino, I. Alter, T.M. Fitzpatrick, J.C. Rose, and P.A. Kot. 1981. Catheterization of the pulmonary artery in the closed-chest rat. Journal of Applied Physiology 51: 1047-1050.
17. Zhu, X.D.; D.M. Shi, Z.C. Jing, Z.C. Jing, L. Li, D. Ma, et al. 2010. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. International Journal of Molecular Medicine 26: 541-547.
18. Varagic, J.; E.D. Frohlich, J. Díez, D. Susic, J. Ahn, A. González, et al. 2006. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. American Journal of Physiology. Heart and Circulatory Physiology 290: 1503-1509.
19. Robbins, I.M. 2004. Advancing therapy for pulmonary arterial hypertension: Can animal models help? American Journal of Respiratory and Critical Care Medicine 169: 5-6.
20. McLaughlin, V.V.; S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, J.R. Lindner, et al. 2009. American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association: ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the AmericanCollege of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. Journal of the American College of Cardiology 53: 1573-1619.
21. Essop, M.R. 2010. Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary arterial hypertension. Cardiovascular Journal of Africa 21: 334-337.
22. Stewart, D.J.; R.D. Levy, P. Cernacek, and D. Langleben. 1991. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Annals of Internal Medicine 114: 464-469.
23. Rubens, C.; R. Ewert, M. Halank, R. Wensel, H.D. Orzechowski, H.P. Schultheiss, et al. 2001. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120: 1562-1569.
24. Djordjevic, T.; R.S. BelAiba, S. Bonello, J. Pfeilschifter, J. Hess, and A. Görlach. 2005. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 519-525.
25. Qi, J.; J. Du, X. Tang, J. Li, B. Wei, and C. Tang. 2004. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart and Vessels 19: 81-88.
26. MacLean, M.R.; D. Alexander, A. Stirrat, M. Gallagher, S.A. Douglas, E.H. Ohlstein, et al. 2000. Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. British Journal of Pharmacology 130: 201-204.
27. Albertin, G.; D. Guidolin, E. Sorato, R. Spinazzi, A. Mascarin, B. Oselladore, et al. 2009. Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. Regulatory Peptides 157: 64-71.
28. Loirand, G.; P. Guerin, and P. Pacaud. 2006. Rho kinases in cardiovascular physiology and pathophysiology. Circulation Research 98: 322-334.
29. Abe, K.; H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, et al. 2004. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circulation Research 94: 385-393.
30. Oka, M.; K.A. Fagan, P.L. Jones, and I.F. McMurtry. 2008. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. British Journal of Pharmacology 155: 444-454.
31. Fukumoto, Y.; T. Matoba, A. Ito, H. Tanaka, T. Kishi, S. Hayashidani, et al. 2005. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391-392.
32. Fujita, H.; Y. Fukumoto, K. Saji, K. Sugimura, J. Demachi, J. Nawata, et al. 2010. Acute vasodilator effects of inhaled fasudil, a specific Rhokinase inhibitor, in patients with pulmonary arterial hypertension. Heart and Vessels 25: 144-149.
33. Ishikura, K.; N. Yamada, M. Ito, S. Ota, M. Nakamura, N. Isaka, et al. 2006. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circulation Journal 70: 174-178.
34. Sauzeau, V.; E.L. Mellionnec, J. Bertoglio, E. Scalbert, P. Pacaud, and G. Loirand. 2001. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by Rho A and Rho-kinase. Circulation Research 88: 1102-1104.
35. Watanabe, T.; R. Pakala, T. Katagiri, and C.R. Benedict. 2001. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. Journal of Hypertension 19: 2191-2196.
36. Rossowski, W.J.; B.L. Cheng, J.E. Taylor, R. Datta, and D.H. Coy. 2002. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. European Journal of Pharmacology 438: 159-170.